Table 6. Non-episodic trials.

Chronic Migraine
Comparison	Outcome	Time point	Effect	Heterogeneity	Quality of Evidence
Propranolol v. Placebo	50% reduction in headache (RR)	42 weeks	2.0 (0.94 to 4.3)	—	Low
Propranolol v. Flunarizine	Headache Frequency (headaches/month)	Baseline	3.0 (0.79 to 5.2)	—	Low
		8 weeks	1.0 (-1.5 to 3.5)	—
Propranolol + Flunarizine vs. Flunarizine	Headache Frequency (headaches/month)	Baseline	2.0 (-0.19 to 4.2)	—	Low
		8 weeks	3.0 (0.56 to 5.4)	—
	50% reduction in headache (RR)	8 weeks	1.3 (0.97 to 1.6)	—	Low
Propranolol v. Nortriptyline	Headache Frequency (Headaches/month)	Baseline	-1.0 (-4.7 to 2.7)	—	Low
		8 weeks	-9.0 (-12.7 to -5.3)	—
Propranolol v. Propranolol + Nortriptyline	Headache Frequency (Headaches/month)	Baseline	-4.0 (-7.8 to -0.24)	—	Low
		8 weeks	-7.0 (-10.8 to -3.3)	—
Propranolol + Topiramate v. Topiramate	Headache Frequency (headaches/month)	Baseline	0.0 (-0.28 to 0.28)	—	Low
		12 weeks	-0.80 (-2.3 to 0.67)	—
	Health Related Quality of Life (MIDAS)	Baseline	0.00 (-0.28 to 0.28)	—	Low
		12 weeks	0.09 (-0.26 to 0.44)	—
	50% reduction in headache (RR)	12 weeks	1.05 (0.63 to 1.7)	—	Low
		24 weeks	1.1 (0.79 to 1.8)	—
Propranolol v. Valproic Acid	Headache Frequency (headaches/month)	8 weeks	4.8 (0.27 to 9.2)	—	Low
Chronic Tension-Type Headache
Pindolol + Amitriptyline v. Placebo	Headache Frequency (headaches/month)	Baseline	1.4 (-2.3 to 5.0)	—	Low
		4 weeks	7.8 (-13.9 to -1.5)	—
		8 weeks	-11.6 (-16.8 to -5.5)	—
	50% reduction in headache (RR)	8 weeks	3.8 (1.5 to 9.3)	—	Low
	Headache Severity (SMD)	Baseline	0.29 (-0.34 to 0.91)	—	Low
		8 weeks	-0.68 (-1.3 to -0.04)	—
Pindolol + Amitriptyline v. Amitriptyline	Headache Frequency (headaches/month)	Baseline	1.6 (-2.2 to 5.3)	—	Low
		4 weeks	0.64 (-5.2 to 6.4)	—
		8 weeks	-1.2 (-6.4 to 4.1)	—
	50% reduction in headache (RR)	8 weeks	1.4 (0.87 to 2.2)	—	Low
	Headache Severity (SMD)	Baseline	3.7 (2.7 to 4.7)	— —	Low
		8 weeks	-0.05 (-0.65 to 0.56)	—